

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Losartan Formulation

Version 9.1      Revision Date: 09/26/2023      SDS Number: 19367-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/07/2014

### SECTION 1. IDENTIFICATION

Product name : Losartan Formulation

#### Manufacturer or supplier's details

Company name of supplier : Organon & Co.  
Address : 30 Hudson Street, 33nd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : 1-551-430-6000  
Emergency telephone : 1-215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Acute toxicity (Oral) : Category 4

Serious eye damage : Category 1

Skin sensitization : Category 1

Reproductive toxicity : Category 1B

Effects on or via lactation

Specific target organ toxicity : Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.  
H302 Harmful if swallowed.  
H317 May cause an allergic skin reaction.  
H318 Causes serious eye damage.  
H360D May damage the unborn child.  
H362 May cause harm to breast-fed children.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

Version 9.1      Revision Date: 09/26/2023      SDS Number: 19367-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/07/2014

H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

### Precautionary Statements

#### Prevention:

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust.  
P263 Avoid contact during pregnancy and while nursing.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P272 Contaminated work clothing must not be allowed out of the workplace.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.

#### Response:

P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.  
P302 + P352 IF ON SKIN: Wash with plenty of soap and water.  
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER.  
P308 + P313 IF exposed or concerned: Get medical attention.  
P333 + P313 If skin irritation or rash occurs: Get medical attention.  
P363 Wash contaminated clothing before reuse.

#### Storage:

P405 Store locked up.

#### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### Other hazards

Contact with dust can cause mechanical irritation or drying of the skin.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

| Chemical name | CAS-No.     | Concentration (% w/w) |
|---------------|-------------|-----------------------|
| Cellulose     | 9004-34-6   | >= 30 - < 50          |
| Losartan      | 124750-99-8 | >= 30 - < 50          |
| Starch        | 9005-25-8   | >= 10 - < 20          |

Actual concentration is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

---

|   |   |  |
|---|---|--|
| General advice  | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.   |
| If inhaled  | : | If inhaled, remove to fresh air.<br>Get medical attention.   |
| In case of skin contact                                     | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse.  |
| In case of eye contact                                      | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.<br>If easy to do, remove contact lens, if worn.<br>Get medical attention immediately.   |
| If swallowed  | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.<br>Never give anything by mouth to an unconscious person.  |
| Most important symptoms and effects, both acute and delayed | : | Harmful if swallowed.<br>May cause an allergic skin reaction.<br>Causes serious eye damage.<br>May damage the unborn child.<br>May cause harm to breast-fed children.<br>May cause damage to organs through prolonged or repeated exposure if swallowed.<br>Contact with dust can cause mechanical irritation or drying of the skin. |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  |
| Notes to physician  | : | Treat symptomatically and supportively.  |

### SECTION 5. FIRE-FIGHTING MEASURES

|                                       |   |   |
|---------------------------------------|---|---|
| Suitable extinguishing media          | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media        | : | None known.   |
| Specific hazards during fire fighting | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products         | : | Carbon oxides<br>Chlorine compounds<br>Nitrogen oxides (NO <sub>x</sub> )   |
| Specific extinguishing methods        | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.   |

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

---

Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Avoid contact during pregnancy and while nursing.  
Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

Version 9.1      Revision Date: 09/26/2023      SDS Number: 19367-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/07/2014

Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

inert or nuisance dust      50 Million particles per cubic foot  
Value type (Form of exposure): TWA (total dust)  
Basis: OSHA Z-3

15 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (total dust)  
Basis: OSHA Z-3

5 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (respirable fraction)  
Basis: OSHA Z-3

15 Million particles per cubic foot  
Value type (Form of exposure): TWA (respirable fraction)  
Basis: OSHA Z-3

Dust, nuisance dust and particulates      10 mg/m<sup>3</sup>  
Value type (Form of exposure): PEL (Total dust)  
Basis: CAL PEL

5 mg/m<sup>3</sup>  
Value type (Form of exposure): PEL (respirable dust fraction)  
Basis: CAL PEL

| Components | CAS-No.   | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis     |
|------------|-----------|-------------------------------|--|-----------|
| Cellulose  | 9004-34-6 | TWA                           | 10 mg/m <sup>3</sup>                           | ACGIH     |
|            |           | TWA (Respirable)              | 5 mg/m <sup>3</sup>                            | NIOSH REL |
|            |           | TWA (total)                   | 10 mg/m <sup>3</sup>                           | NIOSH REL |
|            |           | TWA (total dust)              | 15 mg/m <sup>3</sup>                           | OSHA Z-1  |

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

Version 9.1      Revision Date: 09/26/2023      SDS Number: 19367-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/07/2014

|          |             |                           |                               |           |
|----------|-------------|---------------------------|-------------------------------|-----------|
|          |             | TWA (respirable fraction) | 5 mg/m <sup>3</sup>           | OSHA Z-1  |
| Losartan | 124750-99-8 | TWA                       | 100 µg/m <sup>3</sup> (OEB 2) | Internal  |
| Starch   | 9005-25-8   | TWA                       | 10 mg/m <sup>3</sup>          | ACGIH     |
|          |             | TWA (Respirable)          | 5 mg/m <sup>3</sup>           | NIOSH REL |
|          |             | TWA (total)               | 10 mg/m <sup>3</sup>          | NIOSH REL |
|          |             | TWA (total dust)          | 15 mg/m <sup>3</sup>          | OSHA Z-1  |
|          |             | TWA (respirable fraction) | 5 mg/m <sup>3</sup>           | OSHA Z-1  |

**Engineering measures** : Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).  
If sufficient ventilation is unavailable, use with local exhaust ventilation.

### Personal protective equipment

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

### Hand protection

**Material** : Chemical-resistant gloves

**Remarks** : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often!  
For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Eye protection** : Wear the following personal protective equipment:  
Chemical resistant goggles must be worn.  
If splashes are likely to occur, wear:  
Face-shield

**Skin and body protection** : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

Hygiene measures : Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).  
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

|  |   |   |
|--|---|---|
| Appearance                                       | : | powder  |
| Color  | : | White to light yellow   |
| Odor   | : | No data available   |
| Odor Threshold                                   | : | No data available   |
| pH   | : | No data available   |
| Melting point/freezing point                     | : | No data available   |
| Initial boiling point and boiling range          | : | No data available   |
| Flash point                                      | : | No data available   |
| Evaporation rate                                 | : | No data available   |
| Flammability (solid, gas)                        | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : | No data available   |
| Upper explosion limit / Upper flammability limit | : | No data available   |
| Lower explosion limit / Lower flammability limit | : | No data available   |
| Vapor pressure                                   | : | No data available   |
| Relative vapor density                           | : | No data available   |
| Relative density                                 | : | No data available   |
| Density  | : | 1 g/cm <sup>3</sup>   |
| Solubility(ies)<br>Water solubility              | : | No data available   |
| Partition coefficient: n-                        | : | No data available   |

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

---

octanol/water

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

    Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Minimum ignition energy : > 300 mJ

Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Harmful if swallowed.

#### Product:

Acute oral toxicity : Acute toxicity estimate: 1,502 mg/kg  
Method: Calculation method

#### Components:

**Cellulose:**



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

---

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

### Losartan:

Acute oral toxicity : LD50 (Mouse): 1,257 - 1,590 mg/kg

LDLo (Rat): 200 mg/kg

LDLo (Mouse): 400 mg/kg

### Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Losartan:

Species : Rabbit  
Result : Mild skin irritation

### Serious eye damage/eye irritation

Causes serious eye damage.

### Components:

#### Losartan:

Species : Rabbit  
Result : Severe irritation

### Starch:

Species : Rabbit  
Result : No eye irritation

### Respiratory or skin sensitization

#### Skin sensitization

May cause an allergic skin reaction.

#### Respiratory sensitization

Not classified based on available information.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

Version 9.1      Revision Date: 09/26/2023      SDS Number: 19367-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/07/2014

---

### Components:

#### **Losartan:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Assessment : Probability or evidence of skin sensitization in humans  
Result : positive

#### **Starch:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

#### **Losartan:**

Genotoxicity in vitro : Test Type: in vitro test  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Result: negative

#### **Starch:**

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

Version 9.1      Revision Date: 09/26/2023      SDS Number: 19367-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/07/2014

---

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### **Losartan:**

Species : Mouse  
Application Route : Oral  
Exposure time : 92 weeks  
Dose : 200 mg/kg body weight  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 105 weeks  
Dose : 270 mg/kg body weight  
Result : negative

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### **Reproductive toxicity**

May damage the unborn child.  
May cause harm to breast-fed children.

### **Components:**

#### **Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

---

### Losartan:

- Effects on fertility : Test Type: Fertility  
Species: Rat, female  
Application Route: Oral  
Fertility: LOAEL: 200 mg/kg body weight  
Result: female reproductive effects  
Remarks: Maternal toxicity observed.
- Effects on fetal development : Test Type: Development  
Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 10 mg/kg body weight  
Developmental Toxicity: NOAEL F1: 20 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No teratogenic effects.
- Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: Fetotoxicity., No teratogenic effects.
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.
- Studies indicating a hazard to babies during the lactation period

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

### Components:

#### Losartan:

- Routes of exposure : Ingestion  
Target Organs : Blood, Cardio-vascular system, Stomach, Kidney  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Cellulose:

- Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

Version 9.1      Revision Date: 09/26/2023      SDS Number: 19367-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/07/2014

---

### Losartan:

Species : Rat  
LOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 309 d  
Number of exposures : daily  
Target Organs : Blood, Kidney, Cardio-vascular system, Stomach

Species : Dog  
NOAEL : 5 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Symptoms : Salivation, Vomiting

Species : Dog  
LOAEL : 25 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Number of exposures : daily  
Symptoms : Salivation, Vomiting

### Starch:

Species : Rat  
NOAEL :  $\geq 2,000$  mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Losartan:

No aspiration toxicity classification

### Experience with human exposure

### Components:

#### Losartan:

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: hypotension, tachycardia

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

### Components:

#### Cellulose:

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

---

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

### Losartan:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 929 mg/l  
Exposure time: 96 h  
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 331 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : NOEC (Microcystis aeruginosa (blue-green algae)): 949 mg/l  
Exposure time: 10 d  
Method: FDA 4.01  
  
NOEC (Selenastrum capricornutum (green algae)): 143 mg/l  
Exposure time: 10 d  
Method: FDA 4.01

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 100 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

### Persistence and degradability

#### Components:

##### Cellulose:

Biodegradability : Result: Readily biodegradable.

##### Losartan:

Stability in water : Hydrolysis: < 10 %(5 d)

### Bioaccumulative potential

#### Components:

##### Losartan:

Partition coefficient: n-octanol/water : log Pow: 1.2

##### Mobility in soil

No data available

##### Other adverse effects

No data available

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

---

### SECTION 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

Not regulated as a dangerous good

##### IATA-DGR

Not regulated as a dangerous good

##### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Domestic regulation

##### 49 CFR

Not regulated as a dangerous good

#### Special precautions for user

Not applicable

---

### SECTION 15. REGULATORY INFORMATION

#### CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

#### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

#### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Combustible dust  
Acute toxicity (any route of exposure)  
Respiratory or skin sensitization  
Reproductive toxicity  
Specific target organ toxicity (single or repeated exposure)  
Serious eye damage or eye irritation

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Losartan Formulation

Version 9.1      Revision Date: 09/26/2023      SDS Number: 19367-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/07/2014

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### US State Regulations

#### Pennsylvania Right To Know

|   |             |
|---|-------------|
| Cellulose   | 9004-34-6   |
| Losartan  | 124750-99-8 |
| D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate | 64044-51-5  |
| Starch  | 9005-25-8   |

#### California Permissible Exposure Limits for Chemical Contaminants

|           |           |
|-----------|-----------|
| Cellulose | 9004-34-6 |
| Starch    | 9005-25-8 |


The ingredients of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

## SECTION 16. OTHER INFORMATION

### Further information

#### NFPA 704:



#### HMIS® IV:

|                 |   |   |
|-----------------|---|---|
| HEALTH          | * | 4 |
| FLAMMABILITY    |   | 3 |
| PHYSICAL HAZARD |   | 0 |

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
CAL PEL : California permissible exposure limits for chemical contaminants (Title 8, Article 107)



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

|                 |   |   |
|-----------------|---|---|
| NIOSH REL       | : | USA. NIOSH Recommended Exposure Limits  |
| OSHA Z-1        | : | USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants          |
| OSHA Z-3        | : | USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts                        |
| ACGIH / TWA     | : | 8-hour, time-weighted average   |
| CAL PEL / PEL   | : | Permissible exposure limit  |
| NIOSH REL / TWA | : | Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek |
| OSHA Z-1 / TWA  | : | 8-hour time weighted average  |
| OSHA Z-3 / TWA  | : | 8-hour time weighted average  |

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/26/2023

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Losartan Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 03/20/2023  |
| 9.1     | 09/26/2023     | 19367-00022 | Date of first issue: 10/07/2014 |

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8